Arthur M. Brown
Plus aucun poste en cours
Profil
Arthur M.
Brown has founded two companies, ChanTest Corp.
in 1998 and Laguna Pharmaceuticals, Inc. in 2006.
At ChanTest Corp., he held the title of President & Chief Executive Officer, and at Laguna Pharmaceuticals, Inc., he held the title of Chief Executive Officer.
Anciens postes connus de Arthur M. Brown
| Sociétés | Poste | Fin |
|---|---|---|
Laguna Pharmaceuticals, Inc.
 Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Directeur Général | - |
ChanTest Corp.
 ChanTest Corp. Miscellaneous Commercial ServicesCommercial Services ChanTest Corp. provided testing and discovery services to pharmaceutical and biotech companies. Its services included safety, discovery, cell biology and transporters. The company was founded by Arthur M. Brown in 1998 and was headquartered in Cleveland, OH. | Directeur Général | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
ChanTest Corp.
ChanTest Corp. Miscellaneous Commercial ServicesCommercial Services ChanTest Corp. provided testing and discovery services to pharmaceutical and biotech companies. Its services included safety, discovery, cell biology and transporters. The company was founded by Arthur M. Brown in 1998 and was headquartered in Cleveland, OH. | Commercial Services |
Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Health Technology |
